<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04084847</url>
  </required_header>
  <id_info>
    <org_study_id>895</org_study_id>
    <nct_id>NCT04084847</nct_id>
  </id_info>
  <brief_title>Berberis Vulgaris Consumption and Blood Pressure</brief_title>
  <official_title>Effect of Berberis Vulgaris Consumption on Blood Pressure and Plasma Lipids in Subjects With Cardiovascular Risk Factors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the effect of barberry consumption on systolic and&#xD;
      diastolic blood pressure, serum lipids, and inflammatory status. The study will involve cases&#xD;
      having elevated BP (129/ &lt; 85) and known hypertensive patients on medical treatment. Seventy&#xD;
      people will be randomized into two groups, including intervention (barberry) or placebo&#xD;
      groups.&#xD;
&#xD;
      Before and after of 8 week intervention, 24-hour ambulatory blood pressure monitoring will be&#xD;
      done and fasting venous blood sample will be taken to measure plasma lipids. In addition,&#xD;
      24-hour urine will be collected to measure its sodium content and estimate sodium intake.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 18, 2019</start_date>
  <completion_date type="Actual">October 21, 2020</completion_date>
  <primary_completion_date type="Actual">August 19, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>blood pressure</measure>
    <time_frame>at 8 weeks</time_frame>
    <description>mean of systolic and diastolic blood pressure of participants measured by ambulatory 24 hour blood pressure monitoring</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>lipid profile</measure>
    <time_frame>at 8 weeks</time_frame>
    <description>plasma TC, LDL-C, HDL-C, TG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma NOx</measure>
    <time_frame>at 8 weeks</time_frame>
    <description>concentration of nitrite and nitrate in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory cytokine</measure>
    <time_frame>at 8 weeks</time_frame>
    <description>Plasma Interleukin-6</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Blood Pressure</condition>
  <condition>Cardiovascular Risk Factor</condition>
  <condition>Lipid Profile</condition>
  <arm_group>
    <arm_group_label>Barberry</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daily consumption of barberry in powder form.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily consumption of placebo powder.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>berberis vulgaris=barberry</intervention_name>
    <description>10 grams of barberry powder will be consumed daily for 8 weeks.</description>
    <arm_group_label>Barberry</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo powder</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  willingness to participate in the study&#xD;
&#xD;
          -  age between 20-65 years&#xD;
&#xD;
          -  having elevated BP (129/ &lt; 85) and known hypertensive patients on medical treatment&#xD;
&#xD;
          -  at least one other classical cardiovascular disease risk factors, including&#xD;
             hyperlipidemia or diabetes mellitus&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unwillingness to continue participation&#xD;
&#xD;
          -  BMI&gt; 30&#xD;
&#xD;
          -  patients on nitrates&#xD;
&#xD;
          -  high doses of statins consumption (Atorvastatin&gt;40 mg/day or Rosuvastatin&gt;20 mg/day)&#xD;
&#xD;
          -  consumption of vitamins or minerals supplements during past month&#xD;
&#xD;
          -  Chronic kidney disease stage 4 or 5&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rajaei Cardiovascular, Medical &amp; Research Center</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 3, 2019</study_first_submitted>
  <study_first_submitted_qc>September 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2019</study_first_posted>
  <last_update_submitted>October 23, 2020</last_update_submitted>
  <last_update_submitted_qc>October 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shahid Beheshti University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Javad Nasrollahzadeh</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>Barberry</keyword>
  <keyword>Berberis vulgaris</keyword>
  <keyword>Blood pressure</keyword>
  <keyword>Lipids</keyword>
  <keyword>Inflammation</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

